XKRX
214370
Market cap1.52bUSD
Oct 08, Last price
41,800.00KRW
1D
-6.07%
1Q
-31.59%
Jan 2017
-49.09%
IPO
-64.15%
Name
Caregen Co Ltd
Chart & performance
P/E
101.64
P/S
28.06
EPS
411.26
Div yield, %
1.05%
Shrs. gr., 5y
-0.15%
Rev. gr., 5y
3.84%
Revenues
72.81b
-11.84%
Net income
20.10b
-37.80%
CFO
18.59b
+37.84%
Dividend
Jun 29, 2026200 KRW/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Caregen Co., Ltd. is primarily involved in the creation and development of biomimetic peptides. The company operates through distinct business segments, each catering to specific markets. Its Professional Therapy division engineers medical devices utilizing functional peptides and sophisticated sustained-release technology. Through its Cosmeceutical line, Caregen offers a variety of products for skin and hair care, including solutions for whitening, anti-inflammatory purposes, and those mimicking botulinum toxin functions. The Health Functional Food division provides dietary supplements specifically designed for blood control. Additionally, the Raw Material segment supplies essential peptide growth factors. Founded on August 17, 2001, the firm is headquartered in Anyang-si, South Korea.
Key people
Yong Ji Jung
Chief Executive Officer, Director
Eun Mi Kim
Director
Heon Ju Jung
Other Non-Executive Director · since 2023
Other Non-Executive Director · since 2023
Jin Seong Choi
Non-Executive Independent Director
Dae Ok Kim
Non-Executive Independent Director
Jung Hyeon Kim
Non-Executive Independent Director
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | |||||||
Unusual Expense (Income) | |||||||
NOPBT | |||||||
NOPBT Margin | |||||||
Operating Taxes | |||||||
Tax Rate | |||||||
NOPAT | |||||||
Net income | |||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | |||||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | |||||||
| Cash flow | |||||||
Cash from operating activities | |||||||
CAPEX | |||||||
Cash from investing activities | |||||||
Cash from financing activities | |||||||
FCF | |||||||
| Balance | |||||||
Cash | |||||||
Long term investments | |||||||
Excess cash | |||||||
Stockholders' equity | |||||||
Invested Capital | |||||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | |||||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | |||||||
EV/EBITDA | |||||||
Interest | |||||||
Interest/NOPBT | |||||||